Recent Updates
Recently added Catalysts
CNMD Neutral Sentiment

CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance

Wednesday, October 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CONMED Corporation reported its third quarter 2026 financial results, revealing sales of $335.6 million, a decrease of 0.7% year-over-year. However, when excluding the impact of strategic exits from GI product offerings, net sales showed an organic increase of 6.7%. The company also updated its financial guidance for the full year 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Net sales increased 6.7% on an organic basis.
  • Company updated its financial guidance for 2026.

CONCERNS & RISKS

  • Sales decreased 0.7% year-over-year.
  • Sales decreased 0.8% on a constant currency basis.

Full Press Release Details

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the third quarter ended September 30, 2026 and updated its financial guidance for the full year ending 2026. Third Quarter 2026 Highlights(1) Sales of $335.6 million decreased 0.7% year-over-year as reported and decreased 0.8% on a constant currency(2) basis. Excluding the impact of the Company’s previously announced strategic exits of GI product offerings, net sales increased 6.7% on an organic c

Frequently Asked Questions

What were CONMED's Q3 2026 sales?

CONMED reported third-quarter sales of $335.6 million for the period ending September 30, 2026.

How did reported sales change year-over-year?

Reported sales decreased by 0.7% compared to the same period in the prior year.

What was the organic sales growth rate?

Excluding strategic exits, net sales increased by 6.7% on an organic constant currency basis.

Did CONMED update its full-year guidance?

Yes, the company issued an updated financial guidance outlook for the full year ending 2026.

ShareAdd on Google
Tags: CNMD CONMED financial results 2026 guidance sales report
Last updated: Oct 28, 2026

Biotech snapshot

Cash runway
$37M liquidity · $0M/mo burn
Low dilution risk